Nieuws en video's - LILLY AND CO - Engels - Pagina 2

Lilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting PR Newswire INDIANAPOLIS, March 5, 2024 INDIANAPOLIS , March 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting Nectin-4, KRAS G12D, and BRM (SMARCA2) will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego . The presentations will include new...

Lilly to Participate in Cowen's 44th Annual Health Care Conference PR Newswire INDIANAPOLIS, Feb. 20, 2024 INDIANAPOLIS , Feb. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 44th Annual Health Care Conference on March 6 , 2024. Anat Ashkenazi, executive vice president and chief financial officer, will take part in a fireside chat at 9:10 a.m., Eastern time . A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's...

Philip Johnson to Retire as Lilly Treasurer PR Newswire INDIANAPOLIS, Feb. 9, 2024 INDIANAPOLIS , Feb. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that after more than 28 years, Philip Johnson , group vice president and treasurer, will retire from the company at the end of February to pursue a new professional opportunity. "Phil has had a meaningful impact on Lilly over the last 28 years," said Anat Ashkenazi, executive vice president and chief financial officer at...

Thinking about buying stock in Foghorn Therapeutics, Oscar Health, Eli Lilly And Co, Palo Alto Networks, or CN ENERGY GROUP? PR Newswire NEW YORK, Feb. 8, 2024 NEW YORK , Feb. 8, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FHTX, OSCR, LLY, PANW, and CNEY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. FHTX:...

Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance PR Newswire INDIANAPOLIS, Feb. 6, 2024 Revenue in Q4 2023 increased 28%. New Products (i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products (ii) revenue increased 9% to $5.27 billion in Q4 2023, led by Verzenio and Jardiance. Pipeline progress included FDA approval of Zepbound for adults with obesity or overweight with weight-related comorbidities and...

Thinking about trading options or stock in General Motors, Meta Platforms, Archer-Daniels-Midland, Eli Lilly, or Celestica? PR Newswire NEW YORK, Jan. 30, 2024 NEW YORK , Jan. 30, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GM, META, ADM, LLY, and CLS. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all...

Johna Norton to Retire as Lilly Executive Vice President of Global Quality PR Newswire INDIANAPOLIS, Jan. 25, 2024 INDIANAPOLIS , Jan. 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Johna Norton , executive vice president of Global Quality, will be retiring after 34 years of service with the company, effective July 31, 2024 . She will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee until her retirement date. An...

Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting PR Newswire INDIANAPOLIS, Jan. 23, 2024 Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant, the first to receive gene therapy in the United States for a genetic form of hearing loss AK-OTOF is a gene therapy being developed for the...

Lilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial Guidance PR Newswire INDIANAPOLIS, Jan. 23, 2024 INDIANAPOLIS , Jan. 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance and guidance. The...

Thinking about trading options or stock in TG Therapeutics, Microsoft, Eli Lilly And Co, Chevron, or Alcon? PR Newswire NEW YORK, Jan. 10, 2024 NEW YORK , Jan. 10, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TGTX, MSFT, LLY, CVX, and ALC. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of...

Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™ PR Newswire INDIANAPOLIS, Jan. 4, 2024 INDIANAPOLIS , Jan. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced LillyDirect ™, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes. LillyDirect offers disease management resources, including access to independent healthcare providers*, tailored support, and direct home delivery of select Lilly...

Lilly to Participate in J.P. Morgan Healthcare Conference PR Newswire INDIANAPOLIS, Jan. 2, 2024 INDIANAPOLIS , Jan. 2, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the 42nd Annual J.P. Morgan Healthcare Conference, Jan. 8-11 , 2024. David A. Ricks, Lilly's chair and CEO, will participate in a fireside chat on Jan. 9 at 5:15 p.m. Eastern time . A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at...

Thinking about buying stock in Cingulate, Gracell Biotechnologies, Eli Lilly, ESSA Pharma, or Coherus Biosciences? PR Newswire NEW YORK, Dec. 27, 2023 NEW YORK , Dec. 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CING, GRCL, LLY, EPIX, and CHRS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. CING:...

Lilly Completes Acquisition of POINT Biopharma PR Newswire INDIANAPOLIS, Dec. 27, 2023 INDIANAPOLIS , Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. "Next generation radioligand therapies hold great promise for delivering...

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023 PR Newswire INDIANAPOLIS, Dec. 18, 2023 INDIANAPOLIS , Dec. 18, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The...

Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting PR Newswire INDIANAPOLIS, Dec. 11, 2023 INDIANAPOLIS , Dec. 11, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated clinical data from the international Phase 1/2 BRUIN trial of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, in adult patients with a range of B-cell...

Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks PR Newswire INDIANAPOLIS, Dec. 11, 2023 People who were randomized to placebo following the lead-in period experienced mean weight regain of 14.8% at 88 weeks, indicating Zepbound led to sustained weight loss compared to placebo Full results from the SURMOUNT-4 study were published in The Journal of the American...

Lilly Announces 15% Dividend Increase, First-Quarter 2024 Dividend PR Newswire INDIANAPOLIS, Dec. 8, 2023 INDIANAPOLIS , Dec. 8, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15% increase in its quarterly dividend and declared a dividend for the first quarter of 2024 of $1.30 per share on outstanding common stock. The dividend is payable on March 8, 2024 to shareholders of record at the close of business on Feb. 15, 2024. About Lilly Lilly...

Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium PR Newswire INDIANAPOLIS, Dec. 5, 2023 Results from MONARCH 3 show a numerical improvement in overall survival (OS) of 13.1 months for women with HR+, HER2- metastatic breast cancer treated with Verzenio plus an aromatase inhibitor in the intent-to-treat population and 14.9 months for women...

Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity PR Newswire INDIANAPOLIS, Dec. 5, 2023 Express Scripts to add Zepbound to National Preferred Formulary INDIANAPOLIS , Dec. 5, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Zepbound ™ (tirzepatide) injection is now available. Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m 2 or greater), or those who are overweight (with a BMI of 27 kg/m 2 or greater)...